Nabriva Therapeutics PLC (NASDAQ:NBRV)
| 0.185 BATS BZX Real-Time Price As of 12:04pm ET |  -0.0012 / -0.64%Today’s Change | 0.17 Today|||52-Week Range 1.40 | -69.11% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $12.0M |
Company Description
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Contact Information
Nabriva Therapeutics Plc 25-28 North Wall Quay Dublin Dublin 1 |
Employees
Shareholders
| Mutual fund holders | 3.78% |
| Other institutional | 1.83% |
| Individual stakeholders | 1.49% |
Top Executives
| Theodore R. Schroeder | Chief Executive Officer & Director |
| Steven P. Gelone | President, Chief Operating Officer & Director |
| Dan Dolan | Chief Financial Officer |
| Christine Guico-Pabia | Chief Medical Officer |
| Jodi VanDerveer | Senior Vice President & Head-Human Resources |
